FILING ANALYSIS · FRIDAY, NOVEMBER 13
Aardvark Therapeutics, Inc. AARD — 8-K: Results of Operations and Financial Condition
neutral
The FDA lifted the clinical hold on ARD-101, and the company has a meeting scheduled with the FDA to discuss its proposed clinical development plan, which is a positive step towards resuming clinical development, but the stock's movement will depend on how investors react to the exploratory data from the terminated HERO and OLE trials, which showed numerically greater HQ-CT score reductions with A
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →